Michael S. Cookson, MD, MMHC, highlights 5 studies in prostate cancer being presented at the 2023 American Urological Association Annual Meeting.
In this video, Urology Times® Co–Editor in Chief Michael S. Cookson, MD, MMHC, discusses 5 studies in prostate cancer being presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Cookson is professor and chair of urology at the University of Oklahoma Health Sciences Center in Oklahoma City.
The following abstracts were previewed:
1. LBA02-09 (Shore et al): EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer
2.LBA02-11 (Aggarwal et al): Updated progression-free survival from PRESTO: a phase 3 randomized study of androgen annihilation for high-risk biochemically relapsed prostate cancer (AFT-19)
3. LBA03-03 (Mian et al): Infectious and non-infectious complications following prostate biopsy: a randomized clinical trial
4. MP29-01 (Saad et al): Rapid, durable, and deep prostate-specific antigen response following addition of darolutamide to androgen-deprivation therapy and docetaxel in ARASENS
5. MP29-02 (Shore et al): Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in the North American population from ARASENS
The management of high-risk localized prostate cancer: Back to the future
April 5th 2024"I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.
Subcutaneous nivolumab meets coprimary pharmacokinetic end points for ccRCC
January 30th 2024Patients in the subcutaneous arm (n = 242) achieved a geometric mean Cavgd28 of 77.373μl/mL (90% CI, 74.555-80.297) compared with 36.875 μl/mL (90% CI, 35.565-38.235) in the IV arm (n = 245), for a geometric mean ratio of 2.098 μl/mL (90% CI, 2.001-2.200).